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transporter (cMOAT), genes correlates with exposure of
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Summary We examined the steady-state levels of mRNA for -y-glutamylcysteine synthetase (-y-GCS), multidrug resistance-associated
protein (MRP) and human canalicular multispecific organic anion transporter (cMOAT) in human lung cancer specimens to elucidate their
roles in relation to platinum drug resistance in vivo. Seventy-six autopsy samples (38 primary tumours and their corresponding normal lung
tissues) obtained from 38 patients were analysed using the quantitative reverse transcription polymerase chain reaction (RT-PCR) method.
Both subunits (heavy and light subunits) of y-GCS expression levels of normal lung and tumour tissues exposed to platinum drugs during life
were significantly higherthan those of non-exposed tissues, whereas onlythe MRP expression levels oftumours were elevated in association
with ante-mortem platinum drug exposure. The y-GCS and MRP expression levels correlated significantly. The cMOAT expression levels did
not correlate with ante-mortem platinum drug exposure. Next, we monitored y-GCS heavy subunit expression levels in peripheral
mononuclear cells of eight previously untreated lung cancer patients after platinum drug administration, which revealed that these drugs
induced y-GCS expression in vivo. These results suggest thaty-GCS expression is induced by platinum drugs in vivo and/orthe physiological
stress response to xenobiotics.
Keywords: y-GCS heavy subunit; y-GCS light subunit; multidrug resistance-associated protein; canalicular multispecific organic anion
transporter; drug resistance
Platinum drugs are used widely for chemotherapy of lung cancer,
but their effectiveness is limited by the development and/or the
de novo existence of resistance to them. Increased intracellular
glutathione (GSH) levels and/or reduced drug accumulation have
been reported to play important roles in platinum drug resistance
(Bungo et al, 1990; Fujiwara et al, 1990; O'Brien and Tew, 1996).
The rate-limiting step enzyme forde novo GSH synthesis, i.e. y-
glutamylcysteine synthetase (y-GCS), has been shown to be a
crucial determinant of the platinum drug sensitivity of tumour
cells (Bailey et al, 1992; Godwin et al, 1992; Mulcahy et al, 1994).
Furthermore, several authors have confirmatively shown that
y-GCS overexpression caused in vitro drug resistance by virtue
of increased GSH levels using the expression-vector transfection
technique (Kurokawa et al, 1995; Mulcahy et al, 1995).
The precise mechanism responsible for membrane transport of
platinum drugs is uncertain, but the ATP-dependent glutathione S-
conjugate export (GS-X) pump has been shown to play an impor-
tant role in their membrane transport and the acquisition of
resistance to them (Ishikawa and Ali-Osman, 1993; Fujii et al,
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1994; Ishikawa et al, 1994; Goto et al, 1995). Although the molec-
ular structure of the GS-X pump has not been identified, several
investigators have suggested that it is identical to the multidrug
resistance-associated protein (MRP) (Jedlitschky etal, 1994; Leier
et al, 1994; Muller et al, 1994) or that MRP is one of several
members of a GS-X pump family (de Vries et al, 1995; Chuman
et al, 1996). Furthermore, the recently cloned human canalicular
multispecific organic anion transporter (cMOAT), a new ATP-
binding cassette (ABC) transporter superfamily, is another candi-
date for the GS-X pump (Buchler et al, 1996; Paulusma et al,
1996; Taniguchi et al, 1996).
In these previous studies, however, only tumour cell lines were
investigated extensively. Therefore, in this study, we examined the
steady-state levels of mRNA for the y-GCS, MRP and cMOAT in
human lung cancer specimens to elucidate their roles in relation to
platinum drug resistance in vivo.
MATERIALS AND METHODS
Patients and samples
Seventy-six autopsy samples (38 primary tumours and their corre-
sponding normal lung tissues) from 38 patients with lung cancer
admitted to Hiroshima University and Chugoku Rousai General
Hospitals from June 1992 to October 1996 were studied. Fresh
specimens ofprimary lung tumours and normal lung tissues were
obtained during autopsy after informed consent had been obtained.
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The tumour specimens were not contaminated by necrotic parts
and normal lung tissues. The tissues were frozen in liquid nitrogen
and stored at -80°C until analysed.
In order to examine gene induction in the human body after
chemotherapy, peripheral mononuclear cells (PMN) were obtained
from eight previously untreated lung cancer patients, who gave
their informed consent. These patients were treated with cisplatin
+ irinotecan hydrochloride (CPT-11), cisplatin + etoposide or
carboplatin + etoposide. They were all men and smokers, five of
whom had small-cell lung cancer (SCLC) and three of whom had
non-small-cell lung cancer (NSCLC); their ages ranged from 41 to
69 years (median 59 years). Five-millilitre heparinized blood
samples were taken just before (0 h) and 6 and 24 h after
completing platinum drug administration, and the PMN were
separated immediately using lymphocyte preparation medium
(Lymphoprep, Nycomed Pharma, Oslo, Norway), as described
previously (Yao et al, 1993).
RNA extraction and reverse transcriptase (RT) reaction
Total cellular RNA was extracted using the guanidinium isothio-
cyanate-phenol method described previously (Ohashi et al, 1996).
We confirmed that the amount of total cellular RNA extracted
from each sample showed almost the same quantity by ethidium
bromide staining. cDNA was synthesized using random hexamer
(Amersham, Buckinghamshire, UK) with Superscript RNase H-
reverse transcriptase (Gibco, Bethesda, MD, USA), as described
previously (Ohashi et al, 1996).
Polymerase chain reaction (PCR) amplification
First, to confirm the harvested RNA quality, the reverse-tran-
scribed cDNA synthesized from the same amount oftotal RNA in
each sample was subjected to PCR amplification using 3-actin
primers. The sequences of its primers were: forward 5'-AAGA-
GAGGCATCCTCACCCT-3' and reverse 5'-TACATG-
GCTGGGGTGTTGAA-3'. The PCR conditions were as described
previously (Ohashi et al, 1996). Twenty amplification cycles using
these primers were carried out, and the PCR products were 218 bp
long, corresponding to ,-actin cDNA. We found that expression
levels of 3-actin from each sample were about the same degree by
ethidium bromide staining, even if it had been obtained from
patients whose intervals between death and autopsy differed.
Therefore, we considered that the quality of harvested RNA from
our samples was acceptable for molecular analysis.
The reverse-transcribed cDNA from each sample was subjected to
PCR amplification using primers based on the y-GCS heavy subunit
(Y-GCSh), y-GCS light subunit (y-GCSl), MRP, cMOAT and 3-actin
(internal control) gene sequences. After pre-denaturation at 94°C for
5 min, the cDNA was added to 5 gl ofPCR mixture, comprising 1 gl
of 10 x PCR buffer (100 mm Tris-HCl, pH 9.0, 500 mM potassium
chloride), 1 ,ul of 15 mm magnesium chloride, 2 ,ul ofdistilled water,
0.2 ,ul of 20 mm dNTPs (Takara, Tokyo, Japan), 0.2 ,ul of 50pM
forward primer, 0.2 ,tl of 50pM reverse primer and 0.4 tl (0.2 u) of
Taq polymerase (Promega, Madison, WI, USA). The full-length
coding regions ofthe y-GCSh and y-GCSl cDNAs ofhuman livery-
GCS have been sequenced (Gipp et al, 1992, 1995), and we designed
and synthesized PCR primers for both subunits of human liver
y-GCS cDNA with the assistance of Advanced Gene Computing
Technologies (Irvine, CA, USA; Mitsuhashi et al, 1994). The
sequences of the used primers were as follows: y-GCSh forward
5'-AGGCCAGATACCFll7ATGATCAGT-3' and reverse 5'-GCTG-
TCTATTGAGTCATATCGGGATTTAC-3'; y-GCSl forward
5'-TGTCTTGGAATGCACTGTATCTCATGC-3' and reverse 5'-
TTCAATAGGAGGTGAAGCAATGATCAC-3'. We used the MRP
primer as described previously (Ishikawa et al, 1996) and designed
and synthesized the cMOAT primer ourselves. The sequences ofthe
MRP and cMOAT primers were: MRP forward 5'-TGGGACTG-
GAATGTCACG-3' and reverse 5'-AGGAATATGCCCCGACTFC-
3'; cMOAT forward 5'-CTAATCTAGCCTACTCCTGC-3' and
reverse 5'-CTGCAGCTCTCTCTTCATGTGC-3'. All the PCR
products were ligated with plasmid vectors and amplified using
competent cells. The sequences oftheir nucleotides were identical to
the corresponding partial cDNA sequences.
Amplification was carried out using a thermal cycler (Geneamp
PCR System 2400; Perkin Elmer Applied Biosystems Division,
Norwalk, CO, USA). Each amplification cycle for the reactions
using they-GCSh, y-GCSl and cMOAT primers comprised denatu-
ration at 94°C for 30 s, annealing at 64°C for 30 s and extension at
72°C for 1 min, followed by a final incubation at 72°C for 7 min,
whereas each cycle for amplification with the MRP primer
comprised denaturation at 94°C for 30 s, annealing at 60°C for
30 s and extension at 72°C for 1 min, followed by a final incuba-
tion at 72°C for 7 min. The PCR products were 221, 196, 293 and
275 base pairs (bp) long, corresponding to y-GCSh, y-GCSI, MRP
and cMOAT cDNA respectively.
In order to determine the optimal number of cycles, the accu-
racy of the quantitative PCR procedure was tested in titration
experiments, as described previously (Ohashi et al, 1996). The
optimal number of cycles for y-GCSh and y-GCSI was 22 and for
MRP and cMOAT was 24. We used the 3-actin gene as the internal
control, and the sequences of its primers and amplification cycles
were as described above.
Quantitation of PCR products and analysis of mRNA
expression
The PCR products were electrophoresed using 2% (w/v) agarose
gels, transferred to nylon membranes (Hybond N+; Amersham)
and subjected to hybridization analysis with 32P-labelled cDNA
probes using procedures described previously (Ohashi et al, 1996).
After washing each filter, the radioactivity level was measured
with a laser imaging analyser (BAS-2000; Fuji Photo Film, Tokyo,
Japan). We used the full-length coding region of human y-GCSh
cDNA as the y-GCSh probe (Kurokawa et al, 1995). The PCR
products of MRP and cMOAT described above were used as the
cDNA probes, and we designed and synthesized PCR primers for
y-GCSI and ,-actin probes with the following sequences: y-GCSI
forward primer, as above, and reverse primer 5'-AAGTTTTC-
TAATTCCTCCCAGTAAGGC-3'; f3-actin forward primer, as
above, and reverse primer 5'-AATGGTGATGACCTGGCCGT-3'.
The PCR products were 255 and 580 bp long, corresponding to
y-GCSI and 3-actin cDNA, respectively, and they were both
subcloned and sequenced as described above.
The radioactivity associated with expression levels in each
sample was expressed relative to that due to 3-actin expression
levels in that sample.
Statistical analysis
Contingency table analyses based on X2 statistics were used to
determine the significance of associations between categorical
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Table 1 Patient characteristics
Patient Sexa Age (years) Smokeb Typec Therapyd Pt dose Last Pt to Death to
no. (mg)e death (months)' autopsy(h)g
1 M 73 + SQ 11
2 F 51 - SM CDDP+VP, CAV, RT 49.6 Gy 169 8 2
3 M 68 + SQ CBDCA 3225 4 2
4 M 61 + SQ CBDCA+VDS 236 10 2
5 M 68 + SM CBDCA+VP, CDDP+VP, CPT-11, CBDCA, RT 18 Gy 790 4 1.5
6 M 50 + AD CBDCA+VP 315 1 2
7 M 51 + AD CBDCA+VP, CBDCA 2520 2 3
8 M 62 + AD 2.5
9 M 64 + AD CBDCA+VP, RT 60 Gy 227 10 15
10 M 64 + SM CDDP+VP, CBDCA, RT 39.6 Gy 1472 2 6
11 M 59 + SQ CDDP, CBDCA+VP 1157 2 14
12 M 61 + AD CBDCA, RT 44 Gy 1470 10 2
13 F 61 - AD CBDCA, CDDP, RT 48.6 Gy 525 5 1
14 M 74 + SM CDDP+VP 39 1 13
15 M 63 + SM CDDP+CPT-11 270 5 13
16 M 67 + LA RT12Gy 7
17 F 44 - AD CBDCA+VP, Topotecan, RT 60 Gy 578 15 15
18 M 70 + SM CDDP+VP 267 5 2
19 M 68 + SQ CDDP+VDS 78 4 16
20 F 73 + AD 12
21 F 69 + SM CDDP+CPT-11, CAE 60 11 1.5
22 M 69 + AD 15
23 M 69 + AD CDDP+VDS, CBDCA, RT 50 Gy 393 24 13.5
24 M 57 + AD CDDP+VDS 85 4 2
25 M 60 + AD Taxol, CDDP+CPT-11 114 7 4
26 M 71 + SM 6
27 M 57 + SQ CDDP+VDS, CDDP+CPT-11, RT 50 Gy 269 1 1
28 F 77 + AD RT9 Gy 1
29 F 77 + SM VP 2
30 M 65 + AD Taxol, CDDP+CPT-11, CDDP+5-FU, VP, RT21 Gy 137 7 3
31 M 86 + AD 2
32 M 69 + SM CBDCA+VP 326 1 9
33 M 78 + SQ CBDCA+VP, RT 50 Gy 630 3 2
34 F 82 + SM CBDCA+VP, VP, RT 45 Gy 315 12 12
35 M 69 + SQ 2
36 M 70 + AD CDDP+VDS, RT 45 Gy 195 36 4
37 M 82 + AD 2
38 M 65 + AD 2
aM, male; F, female. b+, patient who had smoked; -, patient who had never smoked. cSM, small-cell carcinoma; AD, adenocarcinoma; SQ, squamous cell
carcinoma; LA, large-cell carcinoma, dCDDP, cisplatin; CBDCA, carboplatin; VP, etoposide; VDS, vindesine; CPT-11, irinotecan hydrochloride; Taxol, paclitaxel;
5-FU, 5-fluorouracil; CAV, cyclophosphamide + doxorubicin + vincristine; CAE, cyclophosphamide + doxorubicin + etoposide; RT, irradiation. eTotal platinum
dose. 'Interval between final platinum drug administration and death (months). ginterval between death and autopsy (hours).
Table 2 The steady stated mRNA levels of four genes
Gene Platinum exposeda Platinum not exposedb P-value
y-GCSh
Normal lung 0.184 (0.004-4.525) 0.024 (0.003-0.147) 0.0017
Tumour 0.253 (0.005-6.106) 0.021 (0.004-0.400) 0.0008
y-GCSI
Normal lung 0.061 (0.006-3.195) 0.032 (0.021-0.060) 0.0080
Tumour 0.077 (0.012-1.541) 0.028 (0.020-0.071) 0.0001
MRP
Normal lung 0.274 (0.023-2.777) 0.177 (0.063-0.428) NSc
Tumour 0.306 (0.055-3.065) 0.160 (0.016-0.821) 0.0291
cMOAT
Normal lung 0.233 (0.072-0.937) 0.148 (0.075-0.310) NS
Tumour 0.205 (0.053-0.570) 0.147 (0.048-0.309) NS
The steady state mRNA levels of four genes. All data are expressed as medians and ranges, and P-values < 0.05 were considerd to be significant. aGroup of
ante-mortem platinum drug exposed samples. bGroup of ante-mortem platinum drug non-exposed samples. cNot significant.
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variables. Differences between the expression levels of each gene
in tissue samples exposed and not exposed to platinum drugs were
analysed using the Mann-Whitney U-test. All the gene expression
levels were skewed toward higher expression levels and were
subjected to logarithmic transformation so that they approximated
more closely to a normal distribution, and then parametric tests
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were performed. The statistical calculations and tests were
performed using Stat View J4.11 Software (Abacus, CA, USA)
and a Macintosh computer. All the statistical tests were two-sided,
the data were expressed as medians and ranges and differences at
P-values of less than 0.05 were considered to be significant.
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Figure 1 Steady-state mRNA levels for each gene are expressed relative to those of P-actin expression using the RT-PCR method, and the relationships of
(A) y-GCSh, (B) y-GCSI, (C) MRP, (D) cMOAT and (E) Topo expression levels between paired individual tumour and normal lung samples are shown. Open
and solid circles denote tissues exposed and not exposed to platinum drugs ante-mortem respectively
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RESULTS
Patient characteristics
We analysed 76 autopsy samples (38 primary tumours and their
corresponding normal lung tissues) from 38 patients using the RT-
PCR method. The patient characteristics are presented in Table 1.
There were 30 men and eight women; 11 had SCLC, 27 had
NSCLC andthey ranged in age from 44 to 86 years old (median 68
years). Almost all ofthem (35 of38) had been smokers and 26 had
received platinum drug therapy for their tumours.
Relationships between platinum drugs and patient
characteristics
y-GCSh, y-GCSI, MRP and cMOAT gene transcripts were detected
in all the samples tested. In order to investigate the associations
between previous platinum drug exposure and expression of each
of these genes, we grouped the results according to whether the
patient had or had not been exposed to these agents ante mortem.
There were no significant differences in ages, sex, smoking histo-
ries, histology, platinum doses received, intervals between the last
platinum drug administration and death, or intervals from death to
autopsy between each group (data not shown).
The steady-state levels of mRNA for both subunits
of yGCS
We examined the relationships between previous platinum drug
exposure and the steady-state levels of mRNA for both heavy and
light subunits ofy-GCS. As shown inTable 2, they-GCShexpression
levels were higher in exposed samples than in non-exposed samples
(normal lung, P = 0.0017; lung tumour, P = 0.0008), and the y-GCSl
expression levels were also higher in exposed samples than in non-
exposed (normal lung, P = 0.0080; lung tumour, P = 0.0001). There
were significant correlations between the expression levels of both
y-GCS subunits in normal lung and lung tumour samples (y-GCSh:
r = 0.847, P < 0.0001; y-GCSl: r = 0.817, P < 0.0001; Figure 1).
Furthermore, y-GCSh expression correlated with y-GCSl expression
in both normal lung (r = 0.779, P < 0.0001) and lung tumour
(r = 0.691, P < 0.0001) samples. There were no significant correla-
tions between the expression levels ofeither ofbothy-GCS subunits
and the cumulative platinum dose or the interval between the last
platinum drugadministration anddeath, andthere were no significant
differences between the expression levels ofnormal lung and tumour
samples orbetween those ofSCLC and NSCLC samples.
The steady-state levels of mRNA for MRP and cMOAT
We also examined the relationships between previous platinum
drug exposure and the steady-state levels of mRNA for MRP and
cMOAT. As shown in Table 2, the MRP expression levels of the
exposed group were higher than those of the non-exposed group
only for the tumour samples (P = 0.0291). In contrast, there were
no significant differences in cMOAT expression levels between
the exposed and non-exposed groups of normal lung or tumour
samples (Table 2). The expression levels of both MRP and
cMOAT in normal and tumour tissue samples showed moderate
correlations (MRP r = 0.652, P = 0.0003; cMOAT r = 0.497, P =
0.0105; Figure 1). Although, MRP expression correlated signifi-
cantly with y-GCSh expression in both normal lung (r= 0.642, P =
0.0001) and lung tumour (r = 0.616, P = 0.0008), the cMOAT
expression showed no correlation with y-GCSh expression. There
were no significant correlations between the expression levels of
either the MRP or the cMOAT and the cumulative platinum dose
or interval between the last platinum drug administration and
death. There were no differences between the expression levels of
normal lung and those of tumour samples or between those of
SCLC and NSCLC samples.
The steady-state mRNA levels in normal liver
Next, we examined the relationships between previous platinum
drug exposure and y-GCSh, y-GCSI, MRP and cMOAT in normal
liver tissues of 24 patients, from whom we were able to obtain
samples at the same time as the sampling oflung tissues. There were
16 exposed samples andeightnon-exposed samples, and the median
and range expression levels of liver samples were as follows: y-
GCSh, exposed 0.087 (0.004-0.396) and non-exposed 0.033
(0.002-0.073); y-GCSI, exposed 0.134 (0.008-0.647) and non-
exposed 0.081 (0.009-0.212); MRP, exposed 0.081 (0.024-0.399)
and non-exposed 0.082 (0.038-0.153); cMOAT, exposed 0.203
(0.025-0.544) and non-exposed 0.180 (0.070-0.384). In contrast to
the lung sample results, there were no differences between the plat-
inum-exposed and -non-exposed groups in normal liver tissues (y-
GCSh, P = 0.0982; y-GCSl, P = 0.5815; MRP, P = 0.3583; cMOAT,
P> 0.9999).
The steady-state levels of DNA topoisomerase I mRNA
As we considered that the mechanisms responsible for resistance
to DNA topoisomerase I (Topo I) inhibitors and platinum drugs
differ, we reanalysed the Topo I expression data (part ofwhich was
reported by Ohashi et al, 1996), according to the platinum drug
exposure history. As shown in Figure lE, there was no significant
difference between the Topo I expression levels of the platinum-
exposed and -non-exposed groups. The expression levels ofTopo I
in normal and tumour tissue samples showed significant correla-
tion (r = 0.928, P < 0.0001; Figure IE), although the Topo I
expression showed no correlation with y-GCSh expression.
Table 3 The expression levels of y-GCSh in peripheral mononuclear cells after platinum drug administration
rime after the completion of platinum drug infusion (h)
0 6 24
y-GCSh expression 0.109 (0.079-0.176)a 0.225 (0.105-0.752)b 0.267 (0.176-0.533)C
We monitored the y-GCSH expression levels of PMN from eight patients with advanced lung cancer. The y-GCSh expression levels increased after exposure
(P = 0.0048, using repeated measures of ANOVA). aEach value is the median (range) of eight samples. bMedian (range) of six samples (two samples were not
available). cMedian (range) of seven samples (one sample was not available).
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Induction of y-GCSh expression in PMN
In order to determine whether platinum drugs actually induce y-
GCS expression levels in vivo, we monitored the y-GCSh expres-
sion levels ofPMN from eight patients with advanced lung cancer.
As shown in Table 3, the y-GCSh expression levels increased
after exposure to platinum drug in a time-dependent manner
(P = 0.0048, using repeated measures ofANOVA).
DISCUSSION
This is, we believe, the first study to provide detailed data about
the steady-state levels of mRNA for both subunits of y-GCS, in
conjunction with the steady-state levels of mRNA for MRP and
cMOAT in clinical specimens. Our data demonstrated that the
steady-state levels of mRNA for both subunits ofy-GCS and MRP,
but not cMOAT, were significantly higher in tissues that had been
exposed to platinum drugs in vivo than in those that had not.
In previous studies, the steady-state levels of y-GCS mRNA in
relation to drug resistance were investigated using cell lines in
vitro (Bailey et al, 1992; Godwin et al, 1992; Mulcahy et al, 1994,
1995; Goto et al, 1995), and the results led to the general conclu-
sion that increased expression resulted in drug resistance. The
primary mechanism underlying this y-GCS up-regulation-induced
drug resistance was thought to be mediated through increased
GSH levels. Furthermore, a recent transfection study showed that
y-GCS overexpression accompanied enhanced GS-X pump
activity without increasing MRP expression (Kurokawa et al,
1995). Taken together, these and our results suggest that increased
y-GCS expression may be an index of both increased GSH levels
and GS-X pump activity and therefore could be a useful drug
resistance marker in a clinical setting.
To our knowledge, no detailed description of steady-state y-
GCSI mRNA levels in clinical samples has been reported, and
therefore we could not compare our results with those of others.
However, it is not surprising that y-GCSl expression showed a
highly significant correlation with y-GCSh expression and ante-
mortem platinum drug exposure history, because in vitro studies
have demonstrated functional cooperation of y-GCSh and y-GCSl
in GSH synthesis (Huang et al, 1993) and possibly in the GSH-
mediated drug resistance mechanism (Mulcahy et al, 1995).
Although y-GCSl has tended to be overlooked by most investiga-
tors, our results demonstrate that it is important to investigate the
expression levels of y-GCSl as well as those of y-GCSh.
In contrast to our results, Nooter et al (1996) have recently
demonstrated that the steady-state MRP mRNA levels in NSCLC
were higher than those in normal lung tissues. The reason for this
discrepancy is uncertain because Nooter et al (1996) did not make
it clear whether the normal lung tissues that they examined were
obtained from the same patients as those whose lung cancer tissues
were analysed.
Our results confirm those of Kuo et al (1996), who showed that
y-GCS and MRP expression was coordinated, possibly through a
common transcriptional factor. In fact, cis-regulating elements
including AP-1 binding sites are found to be present in the
promoter regions of both genes (Zhu and Center, 1994; Mulcahy
and Gipp, 1995; Yao et al, 1995), although whether both genes are
regulated by AP-1 remains to be elucidated. As similar coordinated
expression of y-GCS and DT-diaphorase has been reported
(O'Dwyer et al, 1996), these findings suggest the existence of an
intricate regulatory network of xenobiotic detoxifying genes.
Therefore, the changes in the level ofMRPexpression could syner-
gize with the increases in the genes encoding y-GCS and might
result in platinum drug resistance. However, recent in vitrofindings
from otherlaboratories have suggested thatoverexpression ofMRP
does not induce cisplatin resistance (Grant et al, 1994) and that
MRP is one of several members of the GS-X pump, but not the
GSH-platinum conjugate export pump (Kurokawa et al, 1995;
Chuman et al, 1996). These data indicate that further studies are
required to determine the relationship between MRP and GSH,
including the role ofy-GCS, in platinum drug resistance.
We detected no clear dose-response relationship between total
platinum drug dose and the steady-state levels ofy-GCS and MRP
mRNA. This may be because the threshold dose of such drugs
required for gene induction is considerably lower than that usually
administered clinically. Furthermore, it is noteworthy that the
expression of each gene in normal liver tissues that had and had
not been exposed to platinum drug ante mortem were virtually
identical. These results suggest that transcriptional regulation of
these xenobiotic detoxifying genes is tissue specific.
The cMOAT gene is a newly discovered member of the ABC
transporter superfamily (Taniguchi et al, 1996) and has been
suggested to participate in platinum drug transport. However, we
observed no association between ante-mortem platinum drug
exposure and the steady-state cMOAT mRNA level. Although the
precise role of cMOAT in platinum drug sensitivity needs further
investigation, our results suggest it does not play a major role in
platinum drug transport and/or resistance.
One criticism of our study is that we used autopsy samples.
However, all the autopsies were performed within 16 h of death,
which has been proved to be acceptable for obtaining mRNAs and
proteins of satisfactory quality (Kleiner et al, 1995). As human
tissue is not only a valuable but also a limited resource for research
outside surgery and pathology departments, we think that molec-
ular analysis of autopsy samples should be encouraged.
Over half(16 of27) of ourpatients who received platinum drug
therapy were also given etoposide as a part of a combination
regimen. As etoposide has been found to persist in tissues for a
few days (Stewart et al, 1993), and our autopsy samples were
taken several months after the final anti-cancer drug administra-
tion, we think that it is difficult to evaluate the impact ofetoposide
co-administration on the expression of the four genes that we
examined.
Furthermore, we detected no differences among the steady-state
levels of y-GCS, MRP or cMOAT mRNA in tumour and normal
lung tissues, suggesting that their increased expression after expo-
sure to platinum drugs is part of the normal stress response to
xenobiotics. Kondo et al (1993) reported that treatment of K-562
cells in culture with heavy metals induced a high level of y-GCSh
expression and that the response to this stress was similar to that
after heat shock stress. Furthermore, Ishikawa et al (1996)
reported that cisplatin induced y-GCSh expression in cisplatin-
resistant human leukaemia HL-60 cells. In accordance with these
in vitro results, we observed that y-GCSh expression level in PMN
increased rapidly after exposure to platinum drugs in vivo.
Whether the platinum drug or platinum itself is responsible for this
in vivo gene induction remains to be elucidated. Although residual
platinum may induce y-GCSh overexpression continuously, as
platinum persists in tissues for several months to years after final
exposure (Tothill et al, 1992), further studies are required to deter-
mine whether acutely exposed and chronically exposed tissues
share a common regulatory mechanism of gene induction.
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ABBREVIATIONS
GSH, glutathione; y-GCS, y-glutamylcysteine synthetase; y-GCSh,
y-GCS heavy subunit; y-GCSl, y-GCS light subunit; GS-X pump,
ATP-dependent glutathione S-conjugate export pump; MRP,
multidrug resistance-associated protein; cMOAT, human canalic-
ular multispecific organic anion transporter; Topo I, DNA topoiso-
merase I; PMN, peripheral mononuclear cells; RT-PCR, reverse
transcription polymerase chain reaction; ABC, ATP-binding
cassette
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